trial · primary record
Osimertinib
Lung Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2029-05-30 |
| Primary endpoint | PFS (Progression-Free Survival) |
| Registry ID | NCT07295821 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:51.463Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07295821
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Osimertinib · compound